7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Stilgren LS et al. | Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. | 2003 | Calcif. Tissue Int. | pmid:14667132 |
Okada T et al. | Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. | 2003 | Clin. Exp. Metastasis | pmid:14669795 |
Sugatani T et al. | Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. | 2003 | J. Cell. Biochem. | pmid:12938156 |
Min JK et al. | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. | 2003 | J. Biol. Chem. | pmid:12893832 |
Teitelbaum SL and Ross FP | Genetic regulation of osteoclast development and function. | 2003 | Nat. Rev. Genet. | pmid:12897775 |
Yamada T et al. | Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. | 2003 | Blood | pmid:12411305 |
Barillé-Nion S and Bataille R | New insights in myeloma-induced osteolysis. | 2003 | Leuk. Lymphoma | pmid:14565645 |
Mandelin J et al. | Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. | 2003 | J Bone Joint Surg Br | pmid:14653607 |
Malyszko J et al. | Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. | 2003 | Transplant. Proc. | pmid:14529897 |
Tazoe M et al. | Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. | 2003 | Arch. Oral Biol. | pmid:12828991 |
Wiethe C et al. | Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. | 2003 | J. Immunol. | pmid:12626542 |
Ueland T et al. | Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12629078 |
Yorke R et al. | Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. | 2003 | Eur. J. Cancer | pmid:12957466 |
Kaneyama K et al. | Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. | 2003 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:12973279 |
Lubberts E et al. | IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. | 2003 | J. Immunol. | pmid:12594294 |
Liu JZ et al. | [The OPG/RANKL/RANK system and bone resorptive disease]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15971575 |
Sabokbar A et al. | Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. | 2003 | J. Orthop. Res. | pmid:12507582 |
Elhasid R et al. | Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. | 2003 | Am. J. Hematol. | pmid:12508266 |
Haynes DR et al. | Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. | 2003 | Rheumatology (Oxford) | pmid:12509625 |
Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |
Smith BB et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | 2003 Sep-Oct | Int. J. Toxicol. | pmid:14555415 |
Theoleyre S et al. | The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. | 2004 | Cytokine Growth Factor Rev. | pmid:15561602 |
Mori T et al. | RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. | 2004 | Nucleic Acids Res. | pmid:15562003 |
Ling JQ and Li JP | [Insulin-like growth factor-II and basic fibroblast growth factor affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2004 | Hua Xi Kou Qiang Yi Xue Za Zhi | pmid:15562643 |
Kumamoto H and Ooya K | Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. | 2004 | J. Oral Pathol. Med. | pmid:14675140 |
Suda K et al. | Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. | 2004 | J. Immunol. | pmid:14764723 |
Brubaker KD et al. | Bone morphogenetic protein signaling in prostate cancer cell lines. | 2004 | J. Cell. Biochem. | pmid:14689587 |
Zhang D et al. | The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. | 2004 | Arch. Oral Biol. | pmid:14693199 |
Okumura S et al. | [Regulatory mechanism of osteoclast differentiation and function]. | 2004 | Nippon Rinsho | pmid:15035103 |
Udagawa N et al. | [Possible role of RANKL in bone resorption]. | 2004 | Nippon Rinsho | pmid:15035104 |
Inoue D | [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. | 2004 | Nippon Rinsho | pmid:15035105 |
Suzuki Y | [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. | 2004 | Nippon Rinsho | pmid:15035106 |
Miyaura C | [LPS]. | 2004 | Nippon Rinsho | pmid:15035108 |
Tanaka Y | [Adhesion molecules in the context with bone remodeling and osteoporosis]. | 2004 | Nippon Rinsho | pmid:15035110 |
Tomoyasu A and Higashio K | [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)]. | 2004 | Nippon Rinsho | pmid:15035190 |
Sohen S | [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases]. | 2004 | Nippon Rinsho | pmid:15035207 |
Tanaka Y | [Secondary osteoporosis due to systemic autoimmune diseases and rheumatic diseases]. | 2004 | Nippon Rinsho | pmid:15035208 |
Fukunaga J and Sugahara T | [Osteoporosis induced by immunosuppressant]. | 2004 | Nippon Rinsho | pmid:15035219 |
Juji T and Tanaka S | [Novel therapeutic approach to bone metabolic disorders using RANKL vaccination]. | 2004 | Nippon Rinsho | pmid:15035230 |
Naumann U et al. | Expression and functional activity of osteoprotegerin in human malignant gliomas. | 2004 | Acta Neuropathol. | pmid:14504888 |
Saidenberg-Kermanac'h N et al. | Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. | 2004 | J. Clin. Immunol. | pmid:15163893 |
Melhus H | Soluble RANKL and risk of nontraumatic fracture. | 2004 | JAMA | pmid:15187049 |
Pennisi P et al. | Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. | 2004 | Osteoporos Int | pmid:14661073 |
Wise GE et al. | Regulation of secretion of osteoprotegerin in rat dental follicle cells. | 2004 | Eur. J. Oral Sci. | pmid:15458504 |
Dai SM et al. | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. | 2004 | Ann. Rheum. Dis. | pmid:15479886 |
Wang JC et al. | Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). | 2004 | Exp. Hematol. | pmid:15504545 |
Chen Q et al. | Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. | 2004 | Horm. Metab. Res. | pmid:15523591 |
Saidenberg-Kermanac'h N et al. | TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. | 2004 | Bone | pmid:15542046 |
Boabaid F et al. | The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts. | 2004 | J. Periodontol. | pmid:15515341 |
Franck H et al. | Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. | 2004 | J. Rheumatol. | pmid:15517638 |
Ueland T | Bone metabolism in relation to alterations in systemic growth hormone. | 2004 | Growth Horm. IGF Res. | pmid:15519248 |
Kitaura H et al. | Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. | 2004 | J. Immunol. | pmid:15470024 |
Price PA et al. | Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. | 2004 | J. Biol. Chem. | pmid:14578360 |
Tian QX and Huang GY | [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts]. | 2004 | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | pmid:15379268 |
Colucci S et al. | T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. | 2004 | Blood | pmid:15308561 |
Miyazaki T et al. | Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. | 2004 | J. Cell. Biochem. | pmid:15372622 |
Jeffcoate W | Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? | 2004 | Diabetologia | pmid:15322748 |
Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
Politou M et al. | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). | 2004 | Br. J. Haematol. | pmid:15327520 |
Erdogan B et al. | Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. | 2004 | Neurol. Res. | pmid:15327755 |
Hofbauer LC and Schoppet M | Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. | 2004 | JAMA | pmid:15280347 |
Kanatani M et al. | Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. | 2004 | J. Cell. Physiol. | pmid:15281085 |
Matsuo K and Ray N | Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. | 2004 | Keio J Med | pmid:15247511 |
Mosheimer BA et al. | Expression and function of RANK in human monocyte chemotaxis. | 2004 | Arthritis Rheum. | pmid:15248232 |
Xu D et al. | Development of a chimaeric receptor approach to study signalling by tumour necrosis factor receptor family members. | 2004 | Biochem. J. | pmid:15250821 |
Terpos E et al. | Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. | 2004 | Leukemia | pmid:15215875 |
Brändström H et al. | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). | 2004 | Blood Press. | pmid:15223723 |
Wilson SE et al. | RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. | 2004 | Invest. Ophthalmol. Vis. Sci. | pmid:15223796 |
Pioletti DP and Kottelat A | The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. | 2004 | Biomaterials | pmid:15172492 |
Livshits G et al. | Genetic influences on the circulating cytokines involved in osteoclastogenesis. | 2004 | J. Med. Genet. | pmid:15173242 |
De Wilde A et al. | A low dose of daidzein acts as an ERbeta-selective agonist in trabecular osteoblasts of young female piglets. | 2004 | J. Cell. Physiol. | pmid:15174095 |
Taranta A et al. | Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease. | 2004 | J. Bone Miner. Res. | pmid:15176994 |
Coetzee M and Kruger MC | Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? | 2004 | South. Med. J. | pmid:15180028 |
Abedin M et al. | Vascular calcification: mechanisms and clinical ramifications. | 2004 | Arterioscler. Thromb. Vasc. Biol. | pmid:15155384 |
Vidal K et al. | Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. | 2004 | Pediatr. Res. | pmid:15155868 |
Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
Naumnik W et al. | Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15638385 |
Franchimont N et al. | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. | 2004 | Clin. Exp. Immunol. | pmid:15544627 |
Eaton CL et al. | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. | 2004 | Prostate | pmid:15042606 |
O' Gradaigh D et al. | Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. | 2004 | Ann. Rheum. Dis. | pmid:15020327 |
Ichinose Y et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. | 2004 | Calcif. Tissue Int. | pmid:15549649 |
Collantes Estévez E and González DomÃnguez J | [Bone Paget's disease in the young adult]. | 2004 | Rev Clin Esp | pmid:15456600 |
Collin-Osdoby P | Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. | 2004 | Circ. Res. | pmid:15564564 |
Sato N et al. | MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. | 2004 | J. Exp. Med. | pmid:15353553 |
Neville-Webbe HL et al. | Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. | 2004 | Breast Cancer Res. Treat. | pmid:15567943 |
Mizutani Y et al. | Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. | 2004 | Cancer | pmid:15386310 |
Haynes DR et al. | Regulation of osteoclast activity in peri-implant tissues. | 2004 | Biomaterials | pmid:15109848 |
Ito S and Hata T | Crystal structure of RANK ligand involved in bone metabolism. | 2004 | Vitam. Horm. | pmid:15110169 |
Hao C et al. | Modulation of TRAIL signaling complex. | 2004 | Vitam. Horm. | pmid:15110173 |
Kiechl S et al. | Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. | 2004 | Circulation | pmid:15117849 |
Pritzker LB et al. | The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. | 2004 | Mol. Biol. Cell | pmid:15064358 |
Salmon P | Loss of chaotic trabecular structure in OPG-deficient juvenile Paget's disease patients indicates a chaogenic role for OPG in nonlinear pattern formation of trabecular bone. | 2004 | J. Bone Miner. Res. | pmid:15068491 |
Morabito N et al. | Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. | 2004 | J. Bone Miner. Res. | pmid:15068494 |
Durán A et al. | The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. | 2004 | Dev. Cell | pmid:14960283 |
Wang FS et al. | Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats. | 2004 | Endocrinology | pmid:14962990 |
Harashima SI et al. | Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. | 2004 | Rheumatology (Oxford) | pmid:14963213 |
Altun A et al. | Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. | 2004 | J. Endocrinol. Invest. | pmid:15648548 |
Kanzaki H et al. | Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. | 2004 | J. Dent. Res. | pmid:15557398 |
Zhang X et al. | Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation. | 2004 | Infect. Immun. | pmid:15557643 |